Amdocs (DOX) just released Q4 and full year fiscal 2026 results that aligned with prior guidance, while its fiscal 2027 outlook indicated weaker revenue and profit expectations related to issues with T-Mobile.
Amdocs shares have climbed recently, with a 30 day share price return of 7.42% and a 90 day share price return of 12.91%. However, the year to date share price return is down 22.12% and the 1 year total shareholder return has declined 22.45%, pointing to improving short term momentum after a tougher longer run.
Contrast Amdocs' recent swings with a curated set of software and tech peers that combine quality fundamentals with compressed valuations by scanning our 35 high quality undervalued stocks today.
Amdocs now trades in a zone where recent price strength, a roughly 21% gap to the average analyst target, and an even wider modeled intrinsic discount all pull in different directions. Where does a reasonable fair value line up in that spread?
Most Popular Narrative: 24% Undervalued
Against Amdocs' last close of $62.43, the most widely followed valuation story on Simply Wall St points to a fair value of $82.03. This puts that narrative meaningfully above where the stock is trading today and frames the recent rebound in a very different light.
At the heart of its operations, Amdocs serves as a critical bridge between legacy infrastructure and modern digital requirements, supporting complex telco IT environments with a focus on business support systems (BSS) and operations support systems (OSS). With a deep, long-standing domain expertise that the company describes as its "native language," Amdocs is currently evolving from its traditional service-provider roots into a GenAI-native transformation specialist.
See why 41 investors see Amdocs as 24% undervalued .
Result: Fair Value of $82.03 (UNDERVALUED)
Still, the Amdocs narrative can be knocked off course if T-Mobile related weakness lingers longer than expected or if telecom clients trim large IT transformation budgets.
Find out about the key risks to this Amdocs narrative .
Next Steps
Plenty in this Amdocs story can look either promising or fragile depending on which datapoint you focus on, so move quickly from headline takes to your own conclusions by weighing the 4 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Amdocs?
If Amdocs has your attention, broaden your watchlist now and line up your next moves with a few focused stock shortlists built from hard numbers.
-
Target resilient compounding potential by reviewing companies flagged in our 35 high quality undervalued stocks that pair quality fundamentals with compressed valuations.
-
Prioritise stability first by scanning the 30 resilient stocks with low risk scores so you can focus on businesses with lower overall risk scores.
-
Hunt for tomorrow's quiet opportunities with the 19 high quality undiscovered gems , where strong fundamentals have not yet attracted broad attention.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DOX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
